Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.
This global race for an effective vaccine is scary. This is what the news should be coveringhttps://t.co/okqw0SE7CM
— Amiejour (@Beloved_Day1) August 21, 2020
The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.
The confirmation of their October goal, first announced last month, helped lift S&P 500 futures briefly on Friday as part of a drumbeat of positive news on inoculation efforts that have the potential to end the threat of damaging lockdowns.
The timeline would make the vaccine one of the fastest-moving in the world. Some analysts expect …